43 results on '"Demiot C"'
Search Results
2. Ethical considerations of the dynamics of clinical trials in an epidemic context: Studies on COVID-19
- Author
-
Bahans, C., Leymarie, S., Malauzat, D., Girard, M., and Demiot, C.
- Published
- 2021
- Full Text
- View/download PDF
3. EARLY ENDOTHELIAL DYSFUNCTION SEVERELY IMPAIRS SKIN BLOOD FLOW RESPONSE TO LOCAL PRESSURE APPLICATION IN STREPTOZOTOCIN-DIABETIC MICE: PS1P9
- Author
-
Sigaudo-Roussel, D., Demiot, C., Fromy, B., Koïtka, A., Abraham, P., and Saumet, J-L
- Published
- 2005
4. P295 Le candésartan empêche nettement la formation d’un ulcère de pression sans effet bénéfique sur sa cicatrisation chez des souris diabétiques et saines
- Author
-
Demiot, C., primary, Nasser, M., additional, Javellaud, J., additional, Hamied, A.M., additional, Botelle, L., additional, Oudart, N., additional, and Achard, J.M., additional
- Published
- 2012
- Full Text
- View/download PDF
5. PO34 Un traitement préventif à l’érythropoïétine améliore la vasodilatation induite par la pression et prévient la formation d’un ulcère de pression chez la souris diabétique exprimant des neuropathies
- Author
-
Demiot, C., primary, Javellaud, J., additional, Hamied, A.M., additional, Botelle, L., additional, Oudart, N., additional, and Achard, J.M., additional
- Published
- 2010
- Full Text
- View/download PDF
6. P14 Le candésartan restaure les fonctions neurovasculaires cutanées nécessaires au développement de la vasodilatation induite par la pression dans un diabète expérimental exprimant une neuropathie sévère
- Author
-
Demiot, C., primary, Dupieux, C., additional, Custaud, M.A., additional, Javellaud, J., additional, Botelle, L., additional, Oudart, N., additional, and Achard, J.M., additional
- Published
- 2009
- Full Text
- View/download PDF
7. Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice
- Author
-
DEMIOT, C, primary, FROMY, B, additional, SAUMET, J, additional, and SIGAUDOROUSSEL, D, additional
- Published
- 2006
- Full Text
- View/download PDF
8. [Interest of a short educational intervention coordinated by community pharmacists for elderly type 2 diabetes patients in a rural area].
- Author
-
Fougère E, Delavaud JM, Filloux C, Danigo A, Fagnère C, Jost J, Teissier MP, and Demiot C
- Abstract
The number of elderly people with type 2 diabetes (T2D) is increasing worldwide. Community pharmacies, thanks to their proximity, provide more easy access to therapeutic education for rural patients. Populations living in isolated areas require specific educational resources related to their condition. The aim of this project was to perform a short (FLASH) educational intervention, coordinated by community pharmacists, and then evaluate the impact of this intervention on patient knowledge of their disease. The study was performed in Issoudun, a rural French town of approximately 10,000 inhabitants. Educational priorities were defined and the project was presented to health authorities and local health professionals. Pharmacies in Issoudun recruited patients, either alone or accompanied by their caregivers. The educational intervention lasted 2h and focused on 4 teaching objectives: knowledge concerning diabetes, diabetic complications and how to monitor them; how to react to hypoglycemia; understanding treatments; and understanding glycated hemoglobin. The impact of this educational intervention was assessed using a questionnaire delivered before the intervention, immediately after, and after 6months. Forty-five patients aged 71±6years with T2D duration of 14±6years were recruited over 6months. Some false beliefs were identified before the intervention. The educational session led to a significant improvement in the percentage of correct answers (before: 60.3%±7.5, after: 99%±0.4, P=0.0002) and at 6months (99.5%±0.3, P=0.0002) compared with the patients' initial knowledge. Almost all false beliefs were corrected by the intervention and patients were able to recall the mechanism of action of their drugs, with the help of a "key and lock" schematic. This short FLASH educational intervention, coordinated by community pharmacists, showed that the model was both interesting to patients and effective. This method could be expanded to other rural communities and medical deserts., (Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice.
- Author
-
Bernard A, Mroué M, Bourthoumieu S, Boyce M, Richard L, Sturtz F, Demiot C, and Danigo A
- Abstract
Among the vinca-alkaloid class, vincristine is a potent chemotherapeutic agent with significant neurotoxic effects and is employed to address a wide spectrum of cancer types. Recently, the therapeutic potential of the cholecystokinin type 2 receptor (CCK2R) as a target for vincristine-induced peripheral neuropathy (VIPN) was demonstrated. In this study, the impact of preventive CCK2R blockade using netazepide (Trio Medicines Ltd., London, UK) was investigated in a mouse model of vincristine-induced peripheral neuropathy. Netazepide is a highly selective CCK2R antagonist under development for the treatment of patients with gastric neuroendocrine tumors caused by hypergastrinemia secondary to chronic autoimmune atrophic gastritis. Vincristine-induced peripheral neuropathy was induced by intraperitoneal injections of vincristine at 100 µg/kg/d for 7 days (D0 to D7). Netazepide (2 mg/kg/d or 5 mg/kg/d, per os) was administered one day before vincristine treatment until D7. Vincristine induced a high tactile allodynia from D1 to D7. VIPN was characterized by dorsal root ganglion neuron (DRG) and intraepidermal nerve fiber (IENF) loss, and enlargement and loss of myelinated axons in the sciatic nerve. Netazepide completely prevented the painful symptoms and nerve injuries induced by vincristine. In conclusion, the fact that netazepide protected against vincristine-induced peripheral neuropathy in a mouse model strongly supports the assessment of its therapeutic potential in patients receiving such chemotherapy.
- Published
- 2024
- Full Text
- View/download PDF
10. Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy.
- Author
-
Mroué M, Bessaguet F, Nizou A, Richard L, Sturtz F, Magy L, Bourthoumieu S, Danigo A, and Demiot C
- Abstract
The occurrence of neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting effect of many commonly-used anticancer agents. Polyvalent human immunoglobulins (hIg), used in the treatment of several peripheral neuropathies, may alleviate neuropathic pain. The aim of this project was to investigate the preventive effect of hIg in two mouse models of CIPN, induced by vincristine (VCR, 100 µg/kg/d) and oxaliplatin (OXP, 6 mg/kg/3d). Human Ig were administered one day before the first injection of chemotherapy. The onset of CIPN and effects of hIg were assessed via functional tests and morphological analyses of sensory nerves. To evaluate the effect of hIg on chemotherapy cytotoxicity, viability assays were performed using hIg (0 to 12 mg/mL) combined with anticancer agents on human cancer cell lines. The preventive treatment with hIg alleviated tactile hypersensitivity and nerve injuries induced by VCR. It also alleviated tactile/cold hypersensitivities and nerve injuries induced by OXP. Treatment with hIg did not affect the cytotoxicity of either chemotherapy. Furthermore, in combination with VCR, hIg potentiated chemo-induced cell death. In conclusion, hIg is a promising therapy to prevent the onset of CIPN and potentiate chemotherapy effect on cancer, reinforcing the interest in hIg in the management of CIPN.
- Published
- 2024
- Full Text
- View/download PDF
11. Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine.
- Author
-
Balayssac D, Durif J, Lambert C, Dalbos C, Chapuy E, Etienne M, Demiot C, Busserolles J, Martin V, and Sapin V
- Abstract
Blood biomarkers, including neurofilament light chain (NfL), have garnered attention as potential indicators for chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting adverse effect of neurotoxic anticancer drugs. However, no blood biomarker has been established for routine application or translational research. This pilot study aimed to evaluate a limited panel of blood biomarkers in rat models of CIPN and their correlations with neuropathic pain. CIPN models were induced through repeated injections of oxaliplatin, paclitaxel, bortezomib, and vincristine. Electronic von Frey testing was used to assess tactile allodynia. Post anticancer injections, serum concentrations of 31 proteins were measured. Allodynia thresholds decreased in anticancer-treated animals compared to controls. No consistent modifications were observed in the biomarkers across CIPN models. The most noteworthy biomarkers with increased concentrations in at least two CIPN models were NfL (paclitaxel, vincristine), MCP-1, and RANTES (oxaliplatin, vincristine). Vincristine-treated animals exhibited strong correlations between LIX, MCP-1, NfL, and VEGF concentrations and tactile allodynia thresholds. No single biomarker can be recommended as a unique indicator of CIPN-related pain. Because of the study limitations (single dose of each anticancer drug, young animals, and single time measurement of biomarkers), further investigations are necessary to define the kinetics, specificities, and sensitivities of MCP-1, RANTES, and NfL.
- Published
- 2023
- Full Text
- View/download PDF
12. A mouse model of sensory neuropathy induced by a long course of monomethyl-auristatin E treatment.
- Author
-
Frachet S, Danigo A, Duchesne M, Richard L, Sturtz F, Magy L, and Demiot C
- Subjects
- Animals, Mice, Oligopeptides toxicity, Disease Models, Animal, Xenograft Model Antitumor Assays, Cell Line, Tumor, Peripheral Nervous System Diseases chemically induced, Antineoplastic Agents pharmacology, Immunoconjugates chemistry
- Abstract
Antibody-drug conjugates (ADCs) are anticancer drugs consisting of a monoclonal antibody, targeting selective tumor antigens, to which has been frequently associated a highly potent cytotoxic agent, the monomethyl auristatin E (MMAE) using a chemical linker. MMAE is a tubulin polymerization inhibitor derived from dolastin-10. These MMAE-ADCs are responsible for peripheral nerve toxicities. Our objective was to develop and characterize a mouse model of MMAE-induced peripheral neuropathy induced by free MMAE injections. MMAE was injected in Swiss mice at 50 μg/kg i.p. every other day for 7 weeks. Assessments of motor and sensory nerve functions were performed once a week on MMAE and Vehicle-treated mice. Sciatic nerve and paw skin were removed at the end of experiment for subsequent immunofluorescence and morphological analysis. MMAE did not affect motor coordination, muscular strength and heat nociception, but significantly induced tactile allodynia in MMAE-treated mice compared with Vehicle-treated mice from day 35 to day 49. MMAE significantly reduced myelinated and unmyelinated axon densities in sciatic nerves and led to a loss of intraepidermal nerve fiber in paw skin. In summary, long course of low dose of MMAE induced a peripheral sensory neuropathy associated with nerve degeneration, without general state alteration. This model may represent a ready accessible tool to screen neuroprotective strategies in the context of peripheral neuropathies induced by MMAE-ADCs., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. Drug repurposing: From the discovery of a useful pharmacological effect to making the treatment available to the patient.
- Author
-
Deplanque D, Fetro C, Ferry A, Lechat P, Beghyn T, Bernard C, Bernasconi A, Bienayme H, Cougoule C, Del Bano J, Demiot C, and Lebrun-Vignes B
- Subjects
- Humans, Public-Private Sector Partnerships, Marketing, Drug Repositioning
- Abstract
The repurposing of a medicine already on the market to a new indication could be an opportunity to respond rapidly to a therapeutic need not yet covered, particularly in the context of rare and neglected diseases, or health emergencies. However, at each stage, difficulties may arise that will prevent the repurposed drug from being provided to patients. Beyond fortuity or a systematic strategy to detect a useful pharmacological effect, the implementation of the preclinical and clinical stages is sometimes complicated by the difficulty of accessing the molecule and its pharmaceutical data. Furthermore, relevant clinical results will not always be sufficient to ensure that a marketing authorisation is obtained or that patients receive satisfactory care. In addition to describing these various obstacles, the round table provided an opportunity to put forward recommendations for overcoming them, in particular the creation of a public-private partnership structure with sufficient funding to be able to offer individualised support for projects up to and including the marketing application., (Copyright © 2022 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Repositionnement des médicaments : de la découverte d’un effet pharmacologique utile à la mise à disposition du traitement pour le patient.
- Author
-
Deplanque D, Fetro C, Ferry A, Lechat P, Beghyn T, Bernard C, Bernasconi A, Bienayme H, Cougoule C, Del Bano J, Demiot C, and Lebrun-Vignes B
- Subjects
- Humans, Drug Repositioning, Patients
- Published
- 2023
- Full Text
- View/download PDF
15. Blockade of Cholecystokinin Type 2 Receptors Prevents the Onset of Vincristine-Induced Neuropathy in Mice.
- Author
-
Bernard A, Danigo A, Mroué M, Rovini A, Richard L, Nizou A, Desmoulière A, Sturtz F, Demiot C, and Bourthoumieu S
- Abstract
Vincristine (VCR) is responsible for the onset of the VCR-induced peripheral neuropathy (VIPN), associated with neuropathic pain. Several reports have strongly linked the cholecystokinin type 2 receptor (CCK2R) to nociceptive modulation. Thus, our aim was to evaluate the effect of CCK2R blockade on the onset of VIPN, as well as its interaction on VCR anticancer efficacy. VCR was administrated in mice for 8 days (100 µg/kg/d, i.p.). Transcriptomic analysis of the dorsal root ganglia (DRG) was performed at day 7 in VCR and control mice. Proglumide (30 mg/kg/d), a CCK1R and CCK2R antagonist, and Ly225910 (1 mg/kg/d), a selective CCK2R antagonist, were administrated one day before and during VCR treatment. Tactile sensitivity was assessed during treatments. Immunofluorescence and morphological analyses were performed on the skin, DRG and sciatic nerve at day 7. The cytotoxicity of VCR in combination with proglumide/Ly225910 was evaluated in human cancer cell lines. Cck2r was highly upregulated in the DRG of VCR mice. Proglumide accelerated the recovery of normal sensitivity, while Ly225910 totally prevented the onset of allodynia and nerve injuries induced by VCR. Proglumide or Ly225910 in combination with VCR did not affect the cytotoxicity of VCR. Targeting CCK2R could therefore be an effective strategy to prevent the onset of VIPN.
- Published
- 2022
- Full Text
- View/download PDF
16. Renin-Angiotensin-System Inhibitors for the Prevention of Chemotherapy-Induced Peripheral Neuropathy: OncoToxSRA, a Preliminary Cohort Study.
- Author
-
Frachet S, Danigo A, Labriffe M, Bessaguet F, Quinchard B, Deny N, Baffert KA, Deluche E, Sturtz F, Demiot C, and Magy L
- Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and dose-limiting adverse side effect of treatment. CIPN affects the oncological prognosis of patients, as well as their quality of life. To date, no specific pharmacological therapy has demonstrated effectiveness in preventing CIPN. Accumulating preclinical evidence suggests that renin-angiotensin system (RAS) inhibitors may have neuroprotective effects. One hundred and twenty patients were included in this observational study and were followed from the beginning of their neurotoxic chemotherapy schedule until their final assessment, at least one month after its cessation. The National Cancer Institute's common toxicity criteria 4.0 (NCI-CTC 4.0) were used to grade the severity of adverse events. Follow-ups also included electrochemical skin conductance and scales for pain, quality of life and disability. Among patients receiving a platinum-based regimen, the mean grade of sensory neuropathy (NCI-CTC 4.0) was significantly lower in the RAS inhibitor group after the end of their anticancer treatment schedule. Because of the observational design of the study, patients in the RAS inhibitor group cumulated comorbidities at risk of developing CIPN. Randomized controlled trials in platinum-based regimens would be worth conducting in the future to confirm the neuroprotective potential of RAS inhibitors during chemotherapy.
- Published
- 2022
- Full Text
- View/download PDF
17. Neuroprotective Effect of Ramipril Is Mediated by AT2 in a Mouse MODEL of Paclitaxel-Induced Peripheral Neuropathy.
- Author
-
Bouchenaki H, Bernard A, Bessaguet F, Frachet S, Richard L, Sturtz F, Magy L, Bourthoumieu S, Demiot C, and Danigo A
- Abstract
Paclitaxel (PTX)-induced peripheral neuropathy (PIPN) induces numerous symptoms affecting patient quality of life, leading to decreased doses or even to cessation of anticancer therapy. Previous studies have reported that a widely used drug, ramipril, improves neuroprotection in several rodent models of peripheral neuropathy. The protective role of the angiotensin II type 2 receptor (AT2) in the central and peripheral nervous systems is well-established. Here, we evaluate the effects of ramipril in the prevention of PIPN and the involvement of AT2 in this effect. Paclitaxel was administered in wild type or AT2-deficient mice on alternate days for 8 days, at a cumulative dose of 8 mg/kg (2 mg/kg per injection). Ramipril, PD123319 (an AT2 antagonist), or a combination of both were administered one day before PTX administration, and daily for the next twenty days. PTX-administered mice developed mechanical allodynia and showed a loss of sensory nerve fibers. Ramipril prevented the functional and morphological alterations in PTX mice. The preventive effect of ramipril against tactile allodynia was completely absent in AT2-deficient mice and was counteracted by PD123319 administration in wild type mice. Our work highlights the potential of ramipril as a novel preventive treatment for PIPN, and points to the involvement of AT2 in the neuroprotective role of ramipril in PIPN.
- Published
- 2022
- Full Text
- View/download PDF
18. Alternative to animal experimentation in pharmacology teaching: Development and validation of an equivalent digital learning tool.
- Author
-
Lawson R, Leymarie S, Nikitopoulos C, Humeau A, Bouchenaki H, Duroux JL, Fourcade L, Karam S, Picard N, and Demiot C
- Subjects
- Animals, Computer-Assisted Instruction methods, Diuretics pharmacology, Educational Measurement, Educational Technology methods, France, Furosemide pharmacology, Humans, Motivation, Rats, Surveys and Questionnaires, Animal Testing Alternatives methods, Education, Pharmacy methods, Pharmacology education, Students, Pharmacy psychology
- Abstract
Regarding animal experiments in pharmacology teaching, ethical considerations led us to examine an alternative approach to the use of living animals. This study aimed to assess whether digital tools could replace live animal experiments in terms of motivation and knowledge acquisition. The study was carried out with students enrolled in the 5th year of the industry/research stream at the Faculty of Pharmacy of the University of Limoges. The participants were randomly assigned to groups of traditional or digital teaching methods, with the common theme of the class being the effect of a diuretic agent (furosemide) in rats. The scenario and learning objectives were identical for the two groups. Before the class and after randomization, the acceptance of the digital educational material was assessed with a scale, which predicts the acceptability of users according to individual dimensions and social representations, followed by the assessment of the motivation by a situational motivation scale (SIMS) for both groups. After the class, the students' motivation was assessed by a questionnaire based on Deci and Ryan's self-determination theory. In the end, the participants were evaluated for homogeneity, based on general knowledge of renal pharmacology, and for knowledge acquisition concerning specific knowledge related to this teaching session. This study revealed a good acceptance of the digital tool and a good motivation toward the digital method among all the students. It found the two teaching methods (digital and traditional) to be equivalent in terms of motivation and knowledge acquisition. In our study, digital pedagogical tools as an alternative to live animals did not affect students' motivation and knowledge acquisition., (© 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
19. The Cholecystokinin Type 2 Receptor, a Pharmacological Target for Pain Management.
- Author
-
Bernard A, Danigo A, Bourthoumieu S, Mroué M, Desmoulière A, Sturtz F, Rovini A, and Demiot C
- Abstract
Over the past decades, accumulating evidence has demonstrated a pivotal role of cholecystokinin type 2 receptor (CCK2R) in pain modulation. The established role of CCK2R activation in directly facilitating nociception has led to the development of several CCK2R antagonists, which have been shown to successfully alleviate pain in several rodent models of pain. However, the outcomes of clinical trials are more modest since they have not demonstrated the expected biological effect obtained in animals. Such discordances of results between preclinical and clinical studies suggest reconsidering our knowledge about the molecular basis of the pharmacology and functioning of CCK2R. This review focuses on the cellular localization of CCK2R specifically in the sensory nervous system and discusses in further detail the molecular mechanisms and signal transduction pathways involved in controlling pain perception. We then provide a comprehensive overview of the most successful compounds targeting CCK2R and report recent advances in pharmacological strategies used to achieve CCK2R modulation. We purposely distinguish between CCK2R benefits obtained in preclinical models and outcomes in clinical trials with different pain etiologies. Lastly, we emphasize the biological and clinical relevance of CCK2R as a promising target for the development of new treatments for pain management.
- Published
- 2021
- Full Text
- View/download PDF
20. Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice.
- Author
-
Bouchenaki H, Danigo A, Bernard A, Bessaguet F, Richard L, Sturtz F, Balayssac D, Magy L, and Demiot C
- Abstract
Oxaliplatin is a key drug for colorectal cancer that causes OXP-induced peripheral neuropathy, a dose-limiting effect characterized by cold and tactile hyperesthesia. The relationship between the sensory nervous system and modulation of the renin-angiotensin system has been described, focusing on pain and neurodegeneration in several animal models. We assessed the effect of the RAS modulator, ramipril, an angiotensin converting-enzyme inhibitor in a mouse model of OXP-induced acute pain syndrome. OXP was administered in Swiss mice at a cumulative dose of 15 mg/kg (3 x 5 mg/kg/3 days, i.p.). RAM was administered i.p. every day from 24 h before the first OXP injection until the end of the experiments. We evaluated OIAS development and treatment effects by sensorimotor tests, intraepidermal nerve fiber and dorsal root ganglia-neuron immunohistochemical analyses, and sciatic nerve ultrastructural analysis. OXP-treated mice showed tactile allodynia and cold hypersensitivity, without motor impairment and evidence of nerve degeneration. RAM prevented cold sensitivity and improved recovery of normal tactile sensitivity in OXP-treated mice. Our finding that RAM alleviates OXP-induced pain is a step towards evaluating its therapeutic potential in patients receiving OXP treatment., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Bouchenaki, Danigo, Bernard, Bessaguet, Richard, Sturtz, Balayssac, Magy and Demiot.)
- Published
- 2021
- Full Text
- View/download PDF
21. An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models.
- Author
-
Bouchenaki H, Danigo A, Sturtz F, Hajj R, Magy L, and Demiot C
- Subjects
- Animals, Antineoplastic Agents pharmacology, Clinical Trials as Topic, Drug Evaluation, Preclinical, Endocannabinoids metabolism, Glutamates drug effects, Humans, NAD metabolism, Neuralgia physiopathology, Oxidative Stress drug effects, Pain drug therapy, Receptors, Serotonin drug effects, Renin-Angiotensin System drug effects, Rodentia, Sphingolipids metabolism, Transient Receptor Potential Channels drug effects, Antineoplastic Agents adverse effects, Neuralgia chemically induced, Neuralgia drug therapy
- Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect induced by a variety of chemotherapeutic agents. Symptoms are mainly sensory: pain, tingling, numbness, and temperature sensitivity. They may require the tapering of chemotherapy regimens or even their cessation; thus, the prevention/treatment of CIPN is critical to increase effectiveness of cancer treatment. However, CIPN management is mainly based on conventional neuropathic pain treatments, with poor clinical efficacy. Therefore, significant effort is made to identify new pharmacological targets to prevent/treat CIPN. Animal modeling is a key component in predicting human response to drugs and in understanding the pathophysiological mechanisms underlying CIPN. In fact, studies performed in rodents highlighted several pharmacological targets to treat/prevent CIPN. This review provides updated information about ongoing clinical trials testing drugs for the management of CIPN and presents some of their proof-of-concept studies conducted in rodent models. The presented drugs target oxidative stress, renin-angiotensin system, glutamatergic neurotransmission, sphingolipid metabolism, neuronal uptake transporters, nicotinamide adenine dinucleotide metabolism, endocannabinoid system, transient receptor potential channels, and serotoninergic receptors. As some clinical trials focus on the effect of the drugs on pain, others evaluate their efficacy by assessing general neuropathy. Moreover, based on studies conducted in rodent models, it remains unclear if some of the tested drugs act in an antinociceptive fashion or have neuroprotective properties. Thus, further investigations are needed to understand their mechanism of action, as well as a global standardization of the methods used to assess efficacy of new therapeutic strategies in the treatment of CIPN., (© 2020 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2021
- Full Text
- View/download PDF
22. The Angiotensin II Type 2 Receptor, a Target for Protection and Regeneration of the Peripheral Nervous System?
- Author
-
Danigo A, Rovini A, Bessaguet F, Bouchenaki H, Bernard A, Sturtz F, Bourthoumieu S, Desmoulière A, Magy L, and Demiot C
- Abstract
Preclinical evidence, accumulated over the past decade, indicates that the angiotensin II type 2 receptor (AT2R) stimulation exerts significant neuroprotective effects in various animal models of neuronal injury, notably in the central nervous system. While the atypical G protein-coupled receptor superfamily nature of AT2R and its related signaling are still under investigation, pharmacological studies have shown that stimulation of AT2R leads to neuritogenesis in vitro and in vivo. In this review, we focus on the potential neuroprotective and neuroregenerative roles of AT2R specifically in the peripheral nervous system (PNS). The first section describes the evidence for AT2R expression in the PNS and highlights current controversies concerning the cellular distribution of the receptor. The second section focuses on AT2R signaling implicated in neuronal survival and in neurite outgrowth. The following sections review the relatively few preclinical studies highlighting the putative neuroprotective and neuroregenerative effects of AT2R stimulation in the context of peripheral neuropathy.
- Published
- 2021
- Full Text
- View/download PDF
23. Skin and Nerve Neovascularization in POEMS Syndrome: Insights From a Small Cohort.
- Author
-
Guibert C, Richard L, Durand S, Maquin F, Demiot C, Vallat JM, Jaccard A, Magy L, and Duchesne M
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Humans, Male, Middle Aged, Nerve Fibers pathology, POEMS Syndrome complications, Skin blood supply, Neovascularization, Pathologic complications, POEMS Syndrome pathology, Peroneal Nerve pathology, Skin pathology, Sural Nerve pathology
- Abstract
Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome is a rare systemic disorder linked to plasma cell dyscrasia and is related to elevation of vascular endothelial growth factor (VEGF). Diagnosis is still challenging and pathophysiology unclear. Because VEGF drives neovascularization, we investigated skin and nerve vascularization in 6 patients with POEMS syndrome compared with 5 control groups of polyneuropathies and healthy subjects (n = 104) from the University Hospital of Limoges between 2009 and 2018. We evaluated loss of small and large fibers in these patients. Skin and nerve vascularization were quantified manually on immunofluorescence using vessel staining (anti-α-SMA antibody). Dermal vascularization was significantly higher in POEMS syndrome than in other groups, but unrelated to loss of small fibers and VEGF. Perineurial vascularization was higher in POEMS syndrome than in healthy controls, and was related to loss of large fibers and VEGF level. Our study highlights the existence of neovascularization in skin of patients with this rare disorder. These data suggest that skin neovascularization could be an additional biomarker to help in the diagnosis and understanding of POEMS syndrome. Moreover, nerve neovascularization, driven by VEGF overexpression, may play a role in the pathophysiology of large fiber loss in this condition., (© 2020 American Association of Neuropathologists, Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
24. [Pharmacological management of neuropathic pain].
- Author
-
Bouchenaki H, Bégou M, Magy L, Hajj R, and Demiot C
- Subjects
- Analgesics therapeutic use, Analgesics, Opioid therapeutic use, Antidepressive Agents therapeutic use, Evidence-Based Practice, Humans, Neuralgia diagnosis, Neuralgia epidemiology, Neuralgia etiology, Pain Management methods, Pain Management statistics & numerical data, Practice Guidelines as Topic standards, Randomized Controlled Trials as Topic statistics & numerical data, Neuralgia drug therapy
- Abstract
Neuropathic pain is defined as pain caused by a lesion or a disease affecting the somatosensory nervous system. Development of neuropathic pain is induced by many pathophysiological mechanisms affecting pain pathways. Neuropathic pain has diverse origins, making its management difficult, hence, many patients with neuropathic pain do not receive appropriate treatment. In 2015, a revision of the Neuropathic Pain Special Interest Group's (NeuPSIG) previous recommendations, based on a systematic review and meta-analysis, evaluated the efficacy of systemic and topical treatments of neuropathic pain. Treatments lines were established using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE), which allows to rate the quality of evidence and the strength of recommendations. First line treatments are gabapentin and pregabalin, noradrenalin and serotonin reuptake inhibitors and tricyclic antidepressants. Capsaicin and lidocaine patches are second line treatments, tramadol and strong opioids are third line treatments. This work also highlighted molecules with inconclusive recommendations or non-recommended pharmacological treatments based on a low quality of evidence, a lack of efficacy or a bad safety profile. The objective of this paper is to present the different treatments and to detail their mechanisms of action., (Copyright © 2019 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
25. Focus on 1,25-Dihydroxyvitamin D3 in the Peripheral Nervous System.
- Author
-
Faye PA, Poumeaud F, Miressi F, Lia AS, Demiot C, Magy L, Favreau F, and Sturtz FG
- Abstract
In this review, we draw attention to the roles of calcitriol (1,25-dihydroxyvitamin D3) in the trophicity of the peripheral nervous system. Calcitriol has long been known to be crucial in phosphocalcium homeostasis. However, recent discoveries concerning its involvement in the immune system, anti-cancer defenses, and central nervous system development suggest a more pleiotropic role than previously thought. Several studies have highlighted the impact of calcitriol deficiency as a promoting factor of various central neurological diseases, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease. Based on these findings and recent publications, a greater role for calcitriol may be envisioned in the peripheral nervous system. Indeed, calcitriol is involved in myelination, axonal homogeneity of peripheral nerves, and neuronal-cell differentiation. This may have useful clinical consequences, as calcitriol supplementation may be a simple means to avoid the onset and/or development of peripheral nervous-system disorders.
- Published
- 2019
- Full Text
- View/download PDF
26. Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia.
- Author
-
Bessaguet F, Danigo A, Bouchenaki H, Duchesne M, Magy L, Richard L, Sturtz F, Desmoulière A, and Demiot C
- Subjects
- Angiotensin II Type 2 Receptor Blockers therapeutic use, Animals, Antineoplastic Agents, Phytogenic toxicity, Biphenyl Compounds, Disease Models, Animal, Diterpenes toxicity, Ganglia, Spinal cytology, Hyperalgesia chemically induced, Hyperalgesia pathology, Imidazoles therapeutic use, Male, Mice, Motor Activity drug effects, Neural Conduction drug effects, Neurons metabolism, Neurotoxins toxicity, Nociception drug effects, Pyridines therapeutic use, Sciatic Nerve pathology, Sciatic Nerve physiopathology, Skin metabolism, Vincristine toxicity, Angiotensin II Type 1 Receptor Blockers therapeutic use, Benzimidazoles therapeutic use, Hyperalgesia drug therapy, Neuroprotective Agents therapeutic use, Tetrazoles therapeutic use
- Abstract
Peripheral neuropathy is the major dose-limiting side effect of many currently used chemotherapies, such as vincristine (VCR). We recently demonstrated that candesartan, an angiotensin II type 1 receptor antagonist, was neuroprotective against resiniferatoxin-induced sensory neuropathy, and that this effect is mediated by stimulation of the angiotensin II type 2 receptor (AT2R). Thus, we evaluated the effect of preventive treatment with candesartan and a specific AT2R agonist, C21, on a mouse model of VCR-induced neuropathy. Vincristine was administered daily for 7 days to male Swiss mice. Treatment with candesartan and C21 was started on day 1, before VCR treatment, and continued until day 7. We evaluated the development of VCR-induced neuropathy and the effect of treatment by functional tests, immunohistochemical analyses of intraepidermal nerve fibers and dorsal root ganglia neurons, and ultrastructural analysis of the sciatic nerve. Mice treated with VCR showed high mechanical allodynia but no modifications of motor performance or mechanical/thermal nociception. Treatment with candesartan and C21 completely restored normal tactile sensitivity of VCR-treated mice. Both drugs prevented VCR-induced nonpeptidergic intraepidermal nerve fiber loss. Only C21 displayed neuroprotective effects against VCR-induced loss and enlargement of myelinated nerve fibers in the sciatic nerve. Our finding that candesartan and C21 are protective against VCR-induced neuropathic pain through AT2R stimulation favors evaluation of its therapeutic potential in patients receiving chemotherapy.
- Published
- 2018
- Full Text
- View/download PDF
27. Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.
- Author
-
Duchesne M, Danigo A, Richard L, Vallat JM, Attarian S, Gonnaud PM, Lacour A, Péréon Y, Stojkovic T, Nave KA, Bertrand V, Nabirotchkin S, Cohen D, Demiot C, and Magy L
- Subjects
- Adult, Biopsy, Charcot-Marie-Tooth Disease genetics, Charcot-Marie-Tooth Disease physiopathology, Female, Humans, Male, Middle Aged, Myelin Proteins genetics, Myelin Proteins metabolism, Myelin Sheath metabolism, Nerve Fibers physiology, Neural Conduction physiology, Severity of Illness Index, Visual Analog Scale, Charcot-Marie-Tooth Disease pathology, Myelin Sheath pathology, Nerve Fibers pathology, Skin pathology
- Abstract
Charcot-Marie-Tooth disease type 1A (CMT1A), the most common form of Charcot-Marie-Tooth diseases, is a demyelinating neuropathy caused by a deletion encompassing the gene coding for PMP22, a myelin protein of the peripheral nervous system. Although myelinated fibers are mostly involved in CMT1A, some patients experience neuropathic pain. We thus investigated whether unmyelinated fibers are lost in CMT1A. Skin biopsies were taken from the distal portion of the leg of 80 patients with CMT1A as part of the PXT30003-01 study and processed for quantification of intraepidermal nerve fiber density (IENFD). Mean IENFD was significantly lower in CMT1A patients than in healthy controls. Although the data were highly dispersed, IENFD tended to decrease with age and was higher overall in female patients and controls than male patients and controls. This study shows that small nerve fibers are affected in CMT1A and that this correlates with pin sensitivity. The density of epidermal Langerhans cells (LCs) was also significantly reduced in CMT1A patients, suggesting the involvement of LCs in neuropathic pain processes. These findings raise several questions concerning the interactions of Schwann cells and LCs with unmyelinated fibers in CMT1A. Moreover, they suggest that factors other than PMP22 gene dosage are involved in small fiber pathology in CMT1A.
- Published
- 2018
- Full Text
- View/download PDF
28. Candesartan prevents resiniferatoxin-induced sensory small-fiber neuropathy in mice by promoting angiotensin II-mediated AT2 receptor stimulation.
- Author
-
Bessaguet F, Danigo A, Magy L, Sturtz F, Desmoulière A, and Demiot C
- Subjects
- Angiotensin II Type 1 Receptor Blockers administration & dosage, Angiotensin II Type 2 Receptor Blockers administration & dosage, Animals, Biphenyl Compounds, Calcitonin Gene-Related Peptide metabolism, Ganglia, Spinal drug effects, Ganglia, Spinal metabolism, Imidazoles administration & dosage, Male, Mice, Mice, Knockout, Pyridines administration & dosage, Ramipril administration & dosage, Receptor, Angiotensin, Type 2 genetics, Sensory Receptor Cells metabolism, Sensory Receptor Cells pathology, Small Fiber Neuropathy chemically induced, Small Fiber Neuropathy metabolism, Substance P metabolism, Angiotensin II administration & dosage, Benzimidazoles administration & dosage, Diterpenes administration & dosage, Neuroprotective Agents administration & dosage, Receptor, Angiotensin, Type 2 metabolism, Sensory Receptor Cells drug effects, Small Fiber Neuropathy prevention & control, Tetrazoles administration & dosage
- Abstract
Sensory defects associated with small-fiber neuropathy (SFN) can lead to profound disabilities. The relationship between the sensory nervous system and modulation of the renin-angiotensin system (RAS) has been described and focused on pain and neurodegeneration in several animal models. We have recently developed an experimental model of functional sensory neuropathy showing thermal hypoalgesia and neuropeptide depletion without nerve fiber degeneration. Here, we aimed to determine whether the modulation of angiotensin II (Ang II) activity could prevent sensory neuropathy induced by RTX. Control and RTX mice received ramipril, an Ang II converting enzyme (ACE) inhibitor, (0.5 mg/kg/day) or candesartan, an Ang II type 1 receptor (AT1R) blocker (0.5 mg/kg/day), one day before vehicle or RTX administration, and each day for the next seven days. Ramipril did not have a beneficial effect in RTX mice, whereas candesartan prevented thermal hypoalgesia and reduced neuropeptide depletion in intraepidermal nerve fibers and dorsal root ganglion neurons. The preventive effect of candesartan was not observed in mice deficient for the Ang II type 2 receptor (AT2R) and was counteracted in wild type mice by EMA200, an AT2R antagonist (3 mg/kg/day). Thus, candesartan may promote AT2R activation by blocking AT1R and increasing Ang II production and enhance its mechanisms of neuroprotection in our RTX model. Our finding that candesartan prevents nociception deficits and neuropeptide depletion encourages the evaluation of its therapeutic potential in patients presenting SFN, particularly those who experience chemotherapy-induced SFN., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
29. Effects of small-fiber neuropathy induced by resiniferatoxin on skin healing and axonal regrowth after burn.
- Author
-
Laverdet B, Girard D, Bayout A, Bordeau N, Demiot C, and Desmoulière A
- Subjects
- Animals, Burns complications, Diterpenes toxicity, Ganglia, Spinal pathology, Ganglia, Spinal physiopathology, Immunoblotting, Immunohistochemistry, Male, Microscopy, Electron, Transmission, Nociception, Rats, Rats, Sprague-Dawley, Sciatic Nerve ultrastructure, Small Fiber Neuropathy chemically induced, Small Fiber Neuropathy complications, Burns physiopathology, Granulation Tissue physiopathology, Nerve Regeneration physiology, Neuronal Outgrowth physiology, Sciatic Nerve physiopathology, Small Fiber Neuropathy physiopathology, Wound Healing physiology
- Abstract
Background: Damage to the peripheral nervous system influences wound healing and, after a deep burn, imperfect cutaneous nerve regeneration occurs. A third-degree burn model was developed in rats combined with the use of resiniferatoxin (RTX), known to promote sensory neuropathy., Methods: Rats were injected intraperitoneally either with RTX or vehicle. A mechanical sensory assay and the hot plate thermal sensory test were performed. The structural integrity of the sciatic nerve was assessed using transmission electron microcopy. After RTX injection, third-degree thermal burns were performed. Wound closure was monitored and samples were collected for histological analysis, immunohistochemistry and immunoblotting for neuronal markers., Results: RTX promoted both mechanical and thermal hypoalgesia. This transient RTX-mediated sensory deficit occurred without damaging the integrity of nerve fibers and induced a significant depletion of neuropeptides in both neuronal bodies and intraepidermal nerve fibers. Although wound closure rates were similar in both groups, the kinetic of granulation tissue remodeling was delayed in the RTX group compared with control group. A significant reduction of the peripherin expression in the RTX group was observed indicating impaired axonal regrowth of small fibers within the wound., Conclusion: Our study confirms the important roles of innervation during skin healing and the defect of nerve regeneration after burn., (Copyright © 2016 Elsevier Ltd and ISBI. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
30. The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials.
- Author
-
Bessaguet F, Magy L, Desmoulière A, and Demiot C
- Subjects
- Animals, Humans, Neuralgia physiopathology, Chronic Pain physiopathology, Renin-Angiotensin System physiology
- Abstract
The prevalence rate of chronic pain is 15% to 25% in adults while the therapeutic arsenal is still insufficient, especially in relieving neuropathic pain. Peripheral pain transmission is conducted by the small Aδ and C sensory nerve fibres. They express elements from the renin-angiotensin-aldosterone system (RAAS), a well-known blood pressure regulator. Recently, studies have demonstrated the role of angiotensin II, its derivatives and aldosterone in the modulation of pain perception, by interacting with receptors expressed by sensory nerve fibres or through the central nervous system. Here, we assess the effects of RAAS modulators in the conduction of pain with molecular, preclinical and clinical approaches, in normal or pathological conditions. Currently, some clinical studies have been carried out on the pain-relieving effect of RAAS modulators and suggest their potential in the management of chronic, inflammatory or neuropathic pain.
- Published
- 2016
- Full Text
- View/download PDF
31. Skin innervation: important roles during normal and pathological cutaneous repair.
- Author
-
Laverdet B, Danigo A, Girard D, Magy L, Demiot C, and Desmoulière A
- Subjects
- Animals, Humans, Nerve Fibers pathology, Regeneration physiology, Wound Healing, Skin innervation, Skin pathology
- Abstract
The skin is a highly sensitive organ. It is densely innervated with different types of sensory nerve endings, which discriminate between pain, temperature and touch. Autonomic nerve fibres which completely derive from sympathetic (cholinergic) neurons are also present. During all the phases of skin wound healing (inflammatory, proliferative and remodelling phases), neuromediators are involved. Several clinical observations indicate that damage to the peripheral nervous system influences wound healing, resulting in chronic wounds within the affected area. Patients with cutaneous sensory defects due to lepromatous leprosy, spinal cord injury and diabetic neuropathy develop ulcers that fail to heal. In addition, numerous experimental observations suggest that neurogenic stimuli profoundly affect wound repair after injury and that delayed wound healing is observed in animal models after surgical resection of cutaneous nerves. All these observations clearly suggest that innervation and neuromediators play a major role in wound healing. Interactions between neuromediators and different skin cells are certainly crucial in the healing process and ultimately the restoration of pain, temperature, and touch perceptions is a major challenge to solve in order to improve patients' quality of life.
- Published
- 2015
- Full Text
- View/download PDF
32. Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice.
- Author
-
Danigo A, Nasser M, Bessaguet F, Javellaud J, Oudart N, Achard JM, and Demiot C
- Subjects
- Angiotensin II Type 1 Receptor Blockers pharmacology, Animals, Benzimidazoles pharmacology, Biphenyl Compounds, Diabetes Mellitus, Experimental complications, Diabetes Mellitus, Experimental pathology, Male, Mice, Microcirculation drug effects, Pressure Ulcer etiology, Pressure Ulcer pathology, Tetrazoles pharmacology, Angiotensin II Type 1 Receptor Blockers therapeutic use, Benzimidazoles therapeutic use, Diabetes Mellitus, Experimental drug therapy, Pressure Ulcer prevention & control, Tetrazoles therapeutic use, Vasodilation drug effects
- Abstract
Background: Angiotensin II type 1 receptor (AT1R) blockers have beneficial effects on neurovascular complications in diabetes and in organ's protection against ischemic episodes. The present study examines whether the AT1R blocker candesartan (1) has a beneficial effect on diabetes-induced alteration of pressure-induced vasodilation (PIV, a cutaneous physiological neurovascular mechanism which could delay the occurrence of tissue ischemia), and (2) could be protective against skin pressure ulcer formation., Methods: Male Swiss mice aged 5-6 weeks were randomly assigned to four experimental groups. In two groups, diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 200 mg.kg(-1)). After 6 weeks, control and STZ mice received either no treatment or candesartan (1 mg/kg-daily in drinking water) during 2 weeks. At the end of treatment (8 weeks of diabetes duration), C-fiber mediated nociception threshold, endothelium-dependent vasodilation and PIV were assessed. Pressure ulcers (PUs) were then induced by pinching the dorsal skin between two magnetic plates for three hours. Skin ulcer area development was assessed during three days, and histological examination of the depth of the skin lesion was performed at day three., Results: After 8 weeks of diabetes, the skin neurovascular functions (C-fiber nociception, endothelium-dependent vasodilation and PIV) were markedly altered in STZ-treated mice, but were fully restored by treatment with candesartan. Whereas in diabetes mice exposure of the skin to pressure induced wide and deep necrotic lesions, treatment with candersartan restored their ability to resist to pressure-induced ulceration as efficiently as the control mice., Conclusion: Candesartan decreases the vulnerability to pressure-induced ulceration and restores skin neurovascular functions in mice with STZ-induced established diabetes.
- Published
- 2015
- Full Text
- View/download PDF
33. Neuroprotective effect of erythropoietin against pressure ulcer in a mouse model of small fiber neuropathy.
- Author
-
Danigo A, Magy L, Richard L, Desmoulière A, Bourthoumieu S, Funalot B, and Demiot C
- Subjects
- Animals, Disease Models, Animal, Diterpenes administration & dosage, Erythromelalgia chemically induced, Mice, Erythromelalgia complications, Erythropoietin therapeutic use, Neuroprotective Agents therapeutic use, Pressure Ulcer prevention & control
- Abstract
An increased risk of skin pressure ulcers (PUs) is common in patients with sensory neuropathies, including those caused by diabetes mellitus. Recombinant human erythropoietin (rhEPO) has been shown to protect the skin against PUs developed in animal models of long-term diabetes. The aim of this work was to determine whether rhEPO could prevent PU formation in a mouse model of drug-induced SFN. Functional SFN was induced by systemic injection of resiniferatoxin (RTX, 50 µg/kg, i.p.). RhEPO (3000 UI/kg, i.p.) was given the day before RTX injection and then every other day. Seven days after RTX administration, PUs were induced by applying two magnetic plates on the dorsal skin. RTX-treated mice expressed thermal and mechanical hypoalgesia and showed calcitonin gene-related peptide (CGRP) and substance P (SP) depletion without nerve degeneration or vascular dysfunction. RTX mice developed significantly larger stage 2 PUs than Vehicle mice. RhEPO prevented thermal and mechanical hypoalgesia and neuropeptide depletion in small nerve fibers. RhEPO increased hematocrit and altered endothelium-dependent vasodilatation without any effect on PU formation in Vehicle mice. The characteristics of PUs in RTX mice treated with rhEPO and Vehicle mice were found similar. In conclusion, RTX appeared to increased PU development through depletion of CGRP and SP in small nerve fibers, whereas systemic rhEPO treatment had beneficial effect on peptidergic nerve fibers and restored skin protective capacities against ischemic pressure. Our findings support the evaluation of rhEPO and/or its non-hematopoietic analogs in preventing to prevent PUs in patients with SFN.
- Published
- 2014
- Full Text
- View/download PDF
34. A reversible functional sensory neuropathy model.
- Author
-
Danigo A, Magy L, Richard L, Sturtz F, Funalot B, and Demiot C
- Subjects
- Animals, Disease Models, Animal, Diterpenes, Epidermis innervation, Ganglia, Spinal pathology, Hot Temperature, Hyperalgesia chemically induced, Hyperalgesia physiopathology, Male, Mice, Myelin Sheath metabolism, Nerve Degeneration chemically induced, Nerve Degeneration pathology, Nerve Fibers, Unmyelinated pathology, Neuralgia pathology, Neuralgia physiopathology, Nociception, Physical Stimulation, Sensory Receptor Cells metabolism, Sensory Receptor Cells pathology, TRPV Cation Channels agonists, Touch, Neuralgia chemically induced
- Abstract
Small-fiber neuropathy was induced in young adult mice by intraperitoneal injection of resiniferatoxin (RTX), a TRPV1 agonist. At day 7, RTX induced significant thermal and mechanical hypoalgesia. At day 28, mechanical and thermal nociception were restored. No nerve degeneration in skin was observed and unmyelinated nerve fiber morphology and density in sciatic nerve were unchanged. At day 7, substance P (SP) was largely depleted in dorsal root ganglia (DRG) neurons, although calcitonin gene-related peptide (CGRP) was only moderately depleted. Three weeks after, SP and CGRP expression was restored in DRG neurons. At the same time, CGRP expression remained low in intraepidermal nerve fibers (IENFs) whereas SP expression had improved. In summary, RTX induced in our model a transient neuropeptide depletion in sensory neurons without nerve degeneration. We think this model is valuable as it brings the opportunity to study functional nerve changes in the very early phase of small fiber neuropathy. Moreover, it may represent a useful tool to study the mechanisms of action of therapeutic strategies to prevent sensory neuropathy of various origins., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
35. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus.
- Author
-
Hamed S, Bennett CL, Demiot C, Ullmann Y, Teot L, and Desmoulière A
- Subjects
- Administration, Topical, Animals, Apoptosis drug effects, Cell Differentiation drug effects, Cell Proliferation drug effects, Cost-Benefit Analysis, Diabetes Mellitus, Experimental immunology, Diabetes Mellitus, Experimental pathology, Female, Humans, Immunity, Cellular, Male, Mice, Neovascularization, Physiologic drug effects, Rats, Recombinant Proteins pharmacology, Skin injuries, Wounds and Injuries immunology, Wounds and Injuries pathology, Diabetes Mellitus, Experimental complications, Erythropoietin pharmacology, Receptors, Erythropoietin metabolism, Regenerative Medicine, Skin metabolism, Wound Healing drug effects, Wounds and Injuries drug therapy
- Abstract
Developing a new drug is expensive: the cost of going from bench to bedside is about $US1 billion. Therefore, the repurposing of an approved drug is potentially rewarding because it expands the drug's existing therapeutic profile and preempts additional development costs. As the safety profile of a repurposed drug is already well known, any new investigations could then focus on its efficacy and other therapeutic benefits. Recombinant erythropoietin (EPO) is a potential candidate for repurposing because the results of numerous studies have shown that systemic and topical EPO is therapeutically beneficial when it is administered to healthy and diabetic animals with acute and chronic skin wounds and burns. Moreover, the molecular mechanisms of EPO's actions have been elucidated: EPO acts on those nonhematopoietic cells which are involved in the innate immune response where it promotes cellular proliferation and differentiation, exerts its cytoprotective actions, and inhibits apoptosis. In this review, the mechanism of EPO's action in skin wound healing is reviewed, and its potential for treating acute and chronic skin wounds and stimulating tissue regeneration in diabetic patients is discussed., (© 2013 by the Wound Healing Society.)
- Published
- 2014
- Full Text
- View/download PDF
36. [TRPV1 in neuropathic pain: from animal models to therapeutical prospects].
- Author
-
Danigo A, Magy L, and Demiot C
- Subjects
- Animals, Clinical Trials as Topic, Disease Models, Animal, Humans, Neuralgia etiology, Neuralgia physiopathology, TRPV Cation Channels physiology, Neuralgia drug therapy, TRPV Cation Channels antagonists & inhibitors
- Abstract
Since its cloning in 1997, functional and structural studies of TRPV1 have led to an improvement in our understanding of the mechanisms that underlie the transduction of noxious thermal and mechanical stimuli by sensory neurons. Because of its role in inflammatory processes and nociceptive pathways, TRPV1 has become an important target for neuropathic pain relief. Models of painful small-fiber sensory neuropathy were developed and several laboratories have progressed in the conception of TRPV1 agonists and antagonists. Patch and cream containing capsaicin, the most famous TRPV1 agonist, are commercialized to relieve neuropathic pain. Others agonists and TRPV1 antagonists are tested in clinical trials and new agents, "TRPV1 modulators", with fewer side effects are currently developed in experimental studies., (© 2013 médecine/sciences – Inserm.)
- Published
- 2013
- Full Text
- View/download PDF
37. Low-magnitude whole body vibration with resistive exercise as a countermeasure against cardiovascular deconditioning after 60 days of head-down bed rest.
- Author
-
Coupé M, Yuan M, Demiot C, Bai YQ, Jiang SZ, Li YZ, Arbeille P, Gauquelin-Koch G, Levrard T, Custaud MA, and Li YH
- Subjects
- Adult, Autonomic Nervous System physiology, Baroreflex, Blood Pressure, Cardiac Output, Heart Rate, Humans, Male, Stroke Volume, Time Factors, Bed Rest, Cardiovascular Deconditioning, Exercise physiology, Vibration
- Abstract
Whole body vibration with resistive exercise is a promising countermeasure against some weightlessness-induced dysfunctions. Our objective was to study whether the combination of low-magnitude whole body vibration with a resistive exercise can prevent the cardiovascular deconditioning induced by a nonstrict 60-day head-down bed rest (Earth Star International Bed Rest Experiment Project). Fourteen healthy men participated in this study. We recorded electrocardiograms and blood pressure waves by means of a noninvasive beat-by-beat measurement system (Cardiospace, integrated by Centre National d'Etudes Spatiales and Astronaut Center of China) during an orthostatic test (20 min of 75-degree head-up tilt test) before and immediately after bed rest. We estimated heart rate, blood pressure, cardiac output, stroke volume, total peripheral resistance, baroreflex sensitivity, and heart rate variability. Low-magnitude whole body vibration with resistive exercise prevented an increase of the sympathetic index (reflecting the sympathovagal balance of cardiac autonomic control) and limited the decrease of the spontaneous baroreflex sensitivity induced by 60 days of head-down bed rest. However, this countermeasure had very little effect on cardiac hemodynamics and did not improve the orthostatic tolerance. This combined countermeasure did not efficiently prevent orthostatic intolerance but prevents changes in the autonomic nervous system associated with cardiovascular deconditioning. The underlying mechanisms remain hypothetical but might involve cutaneous and muscular mechanoreceptors.
- Published
- 2011
- Full Text
- View/download PDF
38. Erythropoietin restores C-fiber function and prevents pressure ulcer formation in diabetic mice.
- Author
-
Demiot C, Sarrazy V, Javellaud J, Gourloi L, Botelle L, Oudart N, and Achard JM
- Subjects
- Animals, Diabetes Mellitus, Experimental chemically induced, Disease Models, Animal, Dose-Response Relationship, Drug, Erythropoietin administration & dosage, Erythropoietin pharmacology, Injections, Intraperitoneal, Magnetics, Male, Mice, Recombinant Proteins administration & dosage, Recombinant Proteins pharmacology, Recombinant Proteins therapeutic use, Skin blood supply, Skin drug effects, Skin innervation, Streptozocin adverse effects, Treatment Outcome, Diabetes Mellitus, Experimental complications, Erythropoietin therapeutic use, Nerve Fibers, Unmyelinated drug effects, Nerve Fibers, Unmyelinated physiology, Pressure Ulcer etiology, Pressure Ulcer prevention & control
- Abstract
Pressure-induced vasodilatation (PIV), a cutaneous physiological neurovascular (C-fiber/endothelium) mechanism, is altered in diabetes and could possibly contribute to pressure ulcer development. We wanted to determine whether recombinant human erythropoietin (rhEPO), which has protective neurovascular effects, could prevent PIV alteration and pressure ulcer formation. We developed a skin pressure ulcer model in mice by applying two magnetic plates to the dorsal skin. This induced significant stage 2 ulcers (assessed visually and histologically) in streptozotocin-treated mice with 8 weeks of diabetes compared with very few in controls. Control and streptozotocin mice received either no treatment or systematic rhEPO (3,000 UI kg(-1) intraperitoneally, twice a week) during the last 2 weeks of diabetes. After 8 weeks of diabetes, we assessed ulcer development, PIV, endothelium-dependent vasodilation, C-fiber-mediated nociception threshold, and skin innervation density. Pretreatment with rhEPO fully prevented ulcer development in streptozotocin mice and also fully restored C-fiber nociception, skin innervation density, and significantly improved PIV, but had no effect on endothelium-dependent vasodilation. Our finding that rhEPO treatment protects the skin against pressure-induced ulcers in diabetic mice encourages evaluation of the therapeutic potential for non-hematopoietic analogs of EPO in preventing neuropathic diabetic ulcers.
- Published
- 2011
- Full Text
- View/download PDF
39. Enforced physical inactivity increases endothelial microparticle levels in healthy volunteers.
- Author
-
Navasiolava NM, Dignat-George F, Sabatier F, Larina IM, Demiot C, Fortrat JO, Gauquelin-Koch G, Kozlovskaya IB, and Custaud MA
- Subjects
- Acetylcholine administration & dosage, Administration, Cutaneous, Biomarkers blood, Blood Glucose metabolism, E-Selectin blood, Endothelial Cells drug effects, Endothelial Cells metabolism, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Endothelium, Vascular physiopathology, Humans, Iontophoresis, Laser-Doppler Flowmetry, Leg, Lipids blood, Male, Microcirculation, Nitroprusside administration & dosage, Time Factors, Vascular Endothelial Growth Factor A blood, Vascular Endothelial Growth Factor Receptor-1 blood, Vasodilation, Vasodilator Agents administration & dosage, Weightlessness Simulation, Young Adult, Cell-Derived Microparticles pathology, Endothelial Cells pathology, Endothelium, Vascular pathology, Sedentary Behavior, Skin blood supply
- Abstract
A sedentary lifestyle has adverse effects on the cardiovascular system, including impaired endothelial functions. Subjecting healthy men to 7 days of dry immersion (DI) presented a unique opportunity to analyze the specific effects of enhanced inactivity on the endothelium. We investigated endothelial properties before, during, and after 7 days of DI involving eight subjects. Microcirculatory functions were assessed with laser Doppler in the skin of the calf. We studied basal blood flow and endothelium-dependent and -independent vasodilation. We also measured plasma levels of microparticles, a sign of cellular dysfunction, and soluble endothelial factors, reflecting the endothelial state. Basal flow and endothelium-dependent vasodilation were reduced by DI (22 + or - 4 vs. 15 + or - 2 arbitrary units and 29 + or - 6% vs. 12 + or - 6%, respectively, P < 0.05), and this was accompanied by an increase in circulating endothelial microparticles (EMPs), which was significant on day 3 (42 + or - 8 vs. 65 + or - 10 EMPs/microl, P < 0.05), whereas microparticles from other cell origins remained unchanged. Plasma soluble VEGF decreased significantly during DI, whereas VEGF receptor 1 and soluble CD62E were unchanged, indicating that the increase in EMPs was associated with a change in antiapoptotic tone rather than endothelial activation. Our study showed that extreme physical inactivity in humans induced by 7 days of DI causes microvascular impairment with a disturbance of endothelial functions, associated with a selective increase in EMPs. Microcirculatory endothelial dysfunction might contribute to cardiovascular deconditioning as well as to hypodynamia-associated pathologies. In conclusion, the endothelium should be the focus of special care in situations of acute limitation of physical activity.
- Published
- 2010
- Full Text
- View/download PDF
40. WISE 2005: chronic bed rest impairs microcirculatory endothelium in women.
- Author
-
Demiot C, Dignat-George F, Fortrat JO, Sabatier F, Gharib C, Larina I, Gauquelin-Koch G, Hughson R, and Custaud MA
- Subjects
- Adult, Bed Rest adverse effects, Blood Flow Velocity, Blood Pressure, Female, Humans, Lower Body Negative Pressure adverse effects, Peripheral Vascular Diseases etiology, Women, Bed Rest methods, Endothelium, Vascular physiopathology, Exercise, Lower Body Negative Pressure methods, Microcirculation physiopathology, Peripheral Vascular Diseases physiopathology
- Abstract
Sedentary behavior has deleterious effects on the cardiovascular system, including reduced endothelial functions. A 2-mo bed rest study in healthy women [women international space simulation for exploration (WISE) 2005 program] presented a unique opportunity to analyze the specific effects of prolonged inactivity without other vascular risk factors on the endothelium. We investigated endothelial properties before and after 56 days of bed rest in 8 subjects who performed no exercise (control group: No-EX) and in 8 subjects who regularly performed treadmill exercise in a lower body negative pressure chamber as well as resistance exercise (countermeasure group, EX). A functional evaluation of the microcirculation in the skin was assessed with laser Doppler. We studied endothelium-dependent and -independent vasodilation using iontophoresis of acetylcholine and sodium nitroprusside, respectively. We also measured circulating endothelial cells (CECs), an index of endothelial damage. In the No-EX group, endothelium-dependent vasodilation was significantly reduced (35.4 +/- 4.8% vs. 24.1 +/- 3.8%, P < 0.05) by bed rest with a significant increase in the number of CECs (3.6 +/- 1.4 vs. 10.6 +/- 2.7 ml(-1), P < 0.05). In the EX group, endothelium-dependent vasodilation and number of CECs were preserved. Our study shows that in humans prolonged bed rest causes impairment of endothelium-dependent function at the microcirculatory level, along with an increase in circulating endothelial cells. Microcirculatory endothelial dysfunction might participate in cardiovascular deconditioning, as well as in several bed rest-induced pathologies. We therefore conclude that the endothelium should be a target for countermeasures during periods of prolonged deconditioning.
- Published
- 2007
- Full Text
- View/download PDF
41. Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy.
- Author
-
Demiot C, Tartas M, Fromy B, Abraham P, Saumet JL, and Sigaudo-Roussel D
- Subjects
- Acetylcholine physiology, Animals, Male, Mice, Nerve Fibers drug effects, Nerve Fibers physiology, Pressure Ulcer drug therapy, Aldehyde Reductase antagonists & inhibitors, Diabetes Mellitus, Experimental physiopathology, Diabetic Neuropathies drug therapy, Enzyme Inhibitors therapeutic use, Imidazolidines therapeutic use, Vasodilation physiology
- Abstract
Pressure-induced vasodilation, a neurovascular mechanism relying on the interaction between mechanosensitive C-fibers and vessels, allows skin blood flow to increase in response to locally nonnociceptive applied pressure that in turn may protect against pressure ulcers. We expected that severe neuropathy would dramatically affect pressure-induced vasodilation in diabetic mice, and we aimed to determine whether pressure-induced vasodilation alteration could be reversed in 8-week diabetic mice. Control and diabetic mice received no treatment or sorbinil, an aldose reductase inhibitor, or alagebrium, an advanced glycation end product breaker, the last 2 weeks of diabetes. Laser Doppler flowmetry was used to evaluate pressure-induced vasodilation and endothelium-dependent vasodilation after iontophoretic delivery of acetylcholine (ACh). We assessed the nervous function with measurements of motor nerve conduction velocity (MNCV) as well as the C-fiber-mediated nociception threshold. Pressure-induced vasodilation, endothelial response, C-fiber threshold, and MNCV were all altered in 8-week diabetic mice. None of the treatments had a significant effect on MNCV. Although sorbinil and alagebrium both restored ACh-dependent vasodilation, sorbinil was the sole treatment to restore the C-fiber threshold as well as pressure-induced vasodilation development. Therefore, the inhibition of aldose reductase pathway by sorbinil improved vascular and C-fiber functions that allow pressure-induced vasodilation restoration that could limit neuropathic diabetic cutaneous pressure ulcers.
- Published
- 2006
- Full Text
- View/download PDF
42. Early endothelial dysfunction severely impairs skin blood flow response to local pressure application in streptozotocin-induced diabetic mice.
- Author
-
Sigaudo-Roussel D, Demiot C, Fromy B, Koïtka A, Lefthériotis G, Abraham P, and Saumet JL
- Subjects
- Animals, Blood Glucose analysis, Body Weight, Diabetes Mellitus, Experimental blood, Diabetes Mellitus, Experimental pathology, Fructosamine blood, Male, Mice, Motor Neurons, Neural Conduction, Pressure, Regional Blood Flow, Sciatic Nerve pathology, Diabetes Mellitus, Experimental physiopathology, Endothelium, Vascular physiopathology, Skin blood supply
- Abstract
Pressure-induced vasodilation (PIV) is a mechanism whereby skin blood flow increases in response to progressive locally applied pressure. Skin blood flow in response to applied pressure decreased early in diabetic patients as a result of vascular and/or neural impairment. This study was designed to determine the effect of vascular changes on PIV in 1-week streptozotocin-induced diabetic mice. We assessed cutaneous microvascular response to local increasing pressure application measured by laser Doppler flowmetry (LDF) and endothelium-dependent and -independent vasodilation by iontophoretic delivery of acetylcholine and sodium nitroprusside and sciatic motor nerve conduction velocity and morphometry. In control mice, LDF increased 34% from baseline to 0.2 kPa external pressure, showing PIV response. In contrast, diabetic mice had no LDF increase in response to progressive external pressure. Moreover, after iontophoretic delivery of acetylcholine, endothelium-dependent vasodilation was largely attenuated in diabetic mice (25%) compared with control mice (81%), whereas vasodilation to sodium nitroprusside was not different between groups. Nerve function as assessed by sciatic nerve conduction velocity and morphometry did not differ between groups. These findings suggest that endothelial impairment is sufficient to severely alter PIV response, which seems to be highly sensitive to endothelial nitric oxide levels. PIV suppression could favor diabetes complications such as diabetic foot ulcers.
- Published
- 2004
- Full Text
- View/download PDF
43. Impaired pressure-induced vasodilation at the foot in young adults with type 1 diabetes.
- Author
-
Koïtka A, Abraham P, Bouhanick B, Sigaudo-Roussel D, Demiot C, and Saumet JL
- Subjects
- Adult, Blood Glucose metabolism, Body Height, Body Weight, Female, Humans, Laser-Doppler Flowmetry, Male, Pressure, Reference Values, Regional Blood Flow, Diabetes Mellitus, Type 1 physiopathology, Diabetic Angiopathies physiopathology, Diabetic Neuropathies physiopathology, Foot blood supply, Skin blood supply, Vasodilation physiology
- Abstract
Vascular and neurological mechanisms are both likely to be involved in foot ulcer. We recently reported a pressure-induced vasodilation (PIV), relying on unmyelinated afferent excitation. We previously found that cutaneous blood flow in response to locally applied pressure might be impaired in diabetic patients because of the combined effects of low cutaneous temperature and alterations in microcirculatory function. Therefore, we aimed to analyze whether, at a relatively high cutaneous temperature, PIV is present in type 1 diabetes and to assess endothelial-dependent vasodilation and endothelium-independent vasodilation. We measured cutaneous blood flow using laser Doppler flowmetry on the head of the first metatarsus in response to applied pressure at 5.0 mmHg/min in warm conditions (29.5 +/- 0.2 degrees C). Responses to iontophoresis of acetylcholine (endothelium dependent) and sodium nitroprusside (endothelium independent) were measured using laser Doppler flowmetry in the forearm. The data indicate that PIV exists at the foot level in normal subjects, whereas it was not found in diabetic patients. In diabetic patients, the nonendothelial-mediated response to sodium nitroprusside was preserved, whereas the endothelial-mediated response to acetylcholine was impaired. These findings might be relevant to the high prevalence of foot ulcer that occurs in diabetic patients.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.